

IQVIA Data Variability Analytics (DVA)


The powerful IQVIA AIML solution that optimizes data integrity by detecting human-driven deviations and errors

Data variability is appropriate and expected during any clinical trial. Clinical parameters such as heart rate and blood pressure, for example, typically vary between patients or within a single patient between time intervals.

But when exceptionally high or low variability occurs due to unintentional human errors or potential misconduct, data integrity is compromised—putting the success of your clinical trial at risk.

Manually reviewing data variability poses challenges, as detection is both elusive and time consuming.

Now, there's *IQVIA Data Variability Analytics* (DVA)—the state-of-theart AIML solution that detects, analyzes, and triggers alerts to data variability—virtually in real time



Superior sensitivity and specificity of *IQVIA Data Variability Analytics* empowers sponsors to "see" data variability transpire in near real-time

CONSPICUOUSLY LOW VARIABILITY



DUPLICATE PATIENT VISITS

'PROFESSIONAL'
SUBJECTS







VITAL SIGN

INTERVARIABILITY





Implausibly consistent data patterns showing abnormally low variation

Repeated vital signs that never change from visit to visit

Including data copied and pasted from previous readouts

Potentially due to sub-optimal data entry policies that ensure accuracy

Potential "professional patients" evading patient identity management

By providing superior detection while easing the burden on sponsors, sites, and researchers, *IQVIA Data Variability Analytics* is gaining traction across the industry

>800
studies, helping clinical study teams better detect risk

Deployed across > 10 customer portfolios

Improved algorithm execution provides results in under 3 minutes

IQVIA Data Variability Analytics gives sponsors a novel solution to:

- **Identify high or suspiciously low data variation due to compromised site processes**—such as duplicate patients—and then alerts your clinical operations team in near real-time to detect potential misconduct.
- **Empowers decision-making** by revealing suspicious variability for human review, providing targeted end-to-end risk mitigation for data integrity and site compliance.
- Renders the time-consuming and cumbersome manual review process virtually obsolete—and is equally applicable to traditional site-based studies, decentralized clinical trials (DCTs), and/or hybrid models.

